|1.||Schally, Andrew V: 6 articles (09/2007 - 01/2005)|
|2.||Varga, Jozsef L: 6 articles (09/2007 - 01/2005)|
|3.||Zarandi, Marta: 6 articles (09/2007 - 01/2005)|
|4.||Halmos, Gabor: 4 articles (09/2007 - 01/2005)|
|5.||Stangelberger, Anton: 4 articles (09/2007 - 01/2005)|
|6.||Groot, Kate: 3 articles (09/2007 - 06/2005)|
|7.||Kanashiro, Celia A: 3 articles (09/2007 - 11/2005)|
|8.||Hammann, Brian D: 3 articles (04/2007 - 08/2005)|
|9.||Armatis, Patricia: 3 articles (11/2005 - 01/2005)|
|10.||Havt, Alexandre: 2 articles (09/2007 - 06/2005)|
|1.||Endometrial Neoplasms (Endometrial Cancer)
06/01/2005 - "Administration of 20 mug MZ-J-7-118, sc, twice a day significantly (P < 0.05) decreased HEC-1A growth, as evidenced by a 57.9% decrease in tumor volume, a 50.7% reduction in tumor weight, and the extension of tumor doubling time from 17.5 +/- 2.8 to 36.4 +/- 6.5 d. "
06/01/2005 - "Treatment of nude mice bearing HEC-1A xenografts with 10 mug/d MZ-J-7-118 for 6 wk significantly inhibited the volume of HEC-1A tumors by 43%, tumor weight by 40% compared with controls and prolonged the tumor doubling time from 18.7 +/- 1.4 to 25.4 +/- 3.8 d. "
08/01/2005 - "Antagonists of GHRH and BN/GRP alone or in combination significantly inhibited growth of PC-3 and DU-145 tumors, the greatest inhibition of tumor volume being achieved by combination of MZ-J-7-118 (5 microg/day) and RC-3940-II (10 microg/day). "
01/01/2005 - "Treatment with MZ-J-7-118, RC-3940-II, or their combination significantly inhibited the growth of PC-3 tumors implanted orthotopically, intraosseously, and s.c. "
01/01/2005 - "The effects of administration of GHRH antagonist MZ-J-7-118, BN/GRP antagonist RC-3940-II, and their combination on the growth and metastatic spread of PC-3 tumors implanted orthotopically into nude mice were evaluated. "
|3.||Prostatic Neoplasms (Prostate Cancer)
09/01/2007 - "Animals bearing androgen-independent LuCaP-35V prostatic cancer model were also treated with MZ-J-7-118. "
08/01/2005 - "We investigated the effects of GHRH antagonists MZ-J-7-118 and RC-J-29-18, BN/GRP antagonists RC-3940-II and RC-3940-Et and the combination of MZ-J-7-118 and RC-3940-II on the growth of PC-3 and DU-145 human androgen independent prostate cancers xenografted s.c. "
09/01/2007 - "We investigated the effect of new GHRH antagonists MZ-J-7-118 and MZ-J-7-138 and luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix or castration on androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancer models xenografted into nude mice. "
11/01/2005 - "Bombesin/gastrin-releasing peptide (BN/GRP) antagonists RC-3940-II and RC-3940-Et, and growth hormone-releasing hormone (GHRH) antagonists MZ-J-7-118 and RC-J-29-18 inhibit the growth of human androgen-independent PC-3 and DU-145 prostate cancers in nude mice. "
|4.||Ovarian Neoplasms (Ovarian Cancer)
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/2007 - "We investigated the effects of bombesin/gastrin-releasing peptide (GRP) antagonist, RC-3940-II, and growth hormone-releasing hormone (GHRH) antagonists, MZ-J-7-114 and MZ-J-7-118, on the expression of epidermal growth factor receptor (EGFR)/HER (-2, -3, and -4) family, angiogenic factors, VEGF-A and VEGF receptors (VEGF-R1 and VEGF-R2), and the apoptotic molecules Bax and Bcl-2, in H-460 and A-549 non-small cell lung carcinomas (NSCLC). "
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|4.||Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
|6.||Vascular Endothelial Growth Factor Receptors (VEGF Receptors)
|7.||Messenger RNA (mRNA)
|8.||Epidermal Growth Factor Receptor (EGF Receptor)
|9.||Gonadotropin-Releasing Hormone (GnRH)
|10.||Epidermal Growth Factor (EGF)
|1.||Heterologous Transplantation (Xenotransplantation)